Hepatic tuberculosis is an extrapulmonary manifestation of tuberculosis involving the liver. It is treated with the same class of systemic therapy used across pulmonary and other extrapulmonary sites of TB disease, following a structured multi-phase course.
Management centres on a full course of antitubercular therapy — delivered in distinct phases targeting bacterial clearance and sterilisation. The specific agents involved and the phase-by-phase schedule are defined in the complete protocol.
Response to therapy is assessed weekly over the first 4–6 weeks. Clinically meaningful markers include resolution of symptoms, weight gain, improving haemoglobin, and a falling C-reactive protein (CRP) — considered more sensitive indicators than ESR alone.